Exploration and Validation of Pancreatic Cancer Hub Genes Based on Weighted Gene Co-Expression Network Analysis and Immune Infiltration Score Analysis

References

• KLein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502. doi:10.1038/s41575-021-00457-x
   PubMed Web of Science ®Google Scholar
• Bisht S, Feldmann G. Novel targets in pancreatic cancer therapy - current status and ongoing translational efforts. Oncol Res Treat. 2018;41(10):596–602. doi:10.1159/000493437
   PubMed Web of Science ®Google Scholar
• Tanaka S. Molecular pathogenesis and targeted therapy of pancreatic cancer. Ann Surg Oncol. 2016;23(Suppl 2):S197–205. doi:10.1245/s10434-015-4463-x
   PubMedGoogle Scholar
• Matsuki R, Arai T, Kogure M, et al. Trends in the treatment of pancreatic cancer in Japan. Biosci Trends. 2021;15(3):135–137. doi:10.5582/bst.2021.01103
   PubMed Web of Science ®Google Scholar
• Neesse A, Algül H, Tuveson DA, et al. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64(9):1476–1484. doi:10.1136/gutjnl-2015-309304
   PubMed Web of Science ®Google Scholar
• Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat. 2021;59:100796. doi:10.1016/j.drup.2021.100796
   PubMed Web of Science ®Google Scholar
• Randazzo O, Papini F, Mantini G, et al. “Open Sesame?”: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity of gemcitabine in pancreatic cancer. Cancers. 2020;12(11):3206. doi:10.3390/cancers12113206
   PubMed Web of Science ®Google Scholar
• Sciarrillo R, Randazzo O, Peters GJ, et al. Exploring splicing modulation as a novel strategy against pancreatic cancer. Design Of Sf3b1 Subunit Modulators Of The Sf3b Spliceosome Complex; 2021:135.
   Google Scholar
• Jiang Y, Chang Y-D, Wang M, et al. Exploring the molecular mechanism of Radix Astragali on colon cancer based on integrated pharmacology and molecular docking technique. World J Tradit Chin Med. 2022;8(4):502. doi:10.4103/2311-8571.355594
   Google Scholar
• Xiao S-X, Li S-J, Fang W-X, et al. Exploring the mechanism of Tripterygium Wilfordii against cancer using network pharmacology and molecular docking. World J Tradit Chin Med. 2022;8(3):417. doi:10.4103/2311-8571.344544
   Google Scholar
• Huang J, Li M, Zhoua W-J, et al. Integrated miRNA and mRNA analysis identified potential mechanisms and targets of qianggan extracts in preventing nonalcoholic steatohepatitis. World J Tradit Chin Med. 2022;8(1):77. doi:10.4103/wjtcm.wjtcm_48_21
   Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9:559. doi:10.1186/1471-2105-9-559
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Liu S, Wang Z, Zhu R, et al. Three differential expression analysis methods for RNA sequencing: limma, EdgeR, DESeq2. J Vis Exp. 2021;175:1.
   Google Scholar
• Zhang Y, Luo J, Liu Z, et al. Identification of hub genes in colorectal cancer based on weighted gene co-expression network analysis and clinical data from the cancer genome atlas. Biosci Rep. 2021;41:7. doi:10.1042/BSR20211280
   Web of Science ®Google Scholar
• Chen S, Yang D, Lei C, et al. Identification of crucial genes in abdominal aortic aneurysm by WGCNA. PeerJ. 2019;7:e7873. doi:10.7717/peerj.7873
   PubMed Web of Science ®Google Scholar
• Zeng D, Ye Z, Shen R, et al. IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol. 2021;12:687975. doi:10.3389/fimmu.2021.687975
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. doi:10.1126/science.1260419
   PubMed Web of Science ®Google Scholar
• Huang H, Zhu L, Huang C, et al. Identification of hub genes associated with clear cell renal cell carcinoma by integrated bioinformatics analysis. Front Oncol. 2021;11:726655. doi:10.3389/fonc.2021.726655
   PubMed Web of Science ®Google Scholar
• Deng H, Hang Q, Shen D, et al. Low expression of CHRDL1 and SPARCL1 predicts poor prognosis of lung adenocarcinoma based on comprehensive analysis and immunohistochemical validation. Cancer Cell Int. 2021;21(1):259. doi:10.1186/s12935-021-01933-9
   PubMed Web of Science ®Google Scholar
• Yang Y, Deng X, Chen X, et al. Landscape of active enhancers developed de novo in cirrhosis and conserved in hepatocellular carcinoma. Am J Cancer Res. 2020;10(10):3157–3178.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen H, Mao B, et al. Transcriptional characterization of the tumor immune microenvironment and its prognostic value for locally advanced lung adenocarcinoma in A Chinese population. Cancer Manag Res. 2019;11:9165–9173. doi:10.2147/CMAR.S209571
   PubMed Web of Science ®Google Scholar
• Zhou P, Li B, Liu F, et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. Mol Cancer. 2017;16(1):52. doi:10.1186/s12943-017-0624-9
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72–81. doi:10.1016/j.canlet.2019.10.013
   PubMed Web of Science ®Google Scholar
• Yan Z, Ohuchida K, Fei S, et al. Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis. J Exp Clin Cancer Res. 2019;38(1):221. doi:10.1186/s13046-019-1226-8
   PubMedGoogle Scholar
• Biffi G, Oni TE, Spielman B, et al. IL1-Induced JAK/STAT signaling is antagonized by TGFβ to Shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9(2):282–301. doi:10.1158/2159-8290.CD-18-0710
   PubMed Web of Science ®Google Scholar
• Lanfredini S, Thapa A, O’Neill E. RAS in pancreatic cancer. Biochem Soc Trans. 2019;47(4):961–972. doi:10.1042/BST20170521
   PubMedGoogle Scholar
• Mortazavi M, Moosavi F, Martini M, et al. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Crit Rev Oncol Hematol. 2022;176:103749. doi:10.1016/j.critrevonc.2022.103749
   PubMed Web of Science ®Google Scholar
• Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263. doi:10.1038/s41392-021-00658-5
   PubMed Web of Science ®Google Scholar
• Sun X, He X, Zhang Y, et al. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut. 2022;71(1):129–147. doi:10.1136/gutjnl-2020-322744
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chandra V, Riquelme Sanchez E, et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J Exp Med. 2020;217:12. doi:10.1084/jem.20190354
   Web of Science ®Google Scholar
• Hu F, Guo F, Zhu Y, et al. IL-17 in pancreatic disease: pathogenesis and pharmacotherapy. Am J Cancer Res. 2020;10(11):3551–3564.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85. doi:10.1016/S0140-6736(16)00141-0
   PubMed Web of Science ®Google Scholar
• Gao Q, Chen X, Duan H, et al. FXYD6: a novel therapeutic target toward hepatocellular carcinoma. Protein Cell. 2014;5(7):532–543. doi:10.1007/s13238-014-0045-0
   PubMed Web of Science ®Google Scholar
• Cuveillier C, Delaroche J, Seggio M, et al. MAP6 is an intraluminal protein that induces neuronal microtubules to coil. Sci Adv. 2020;6(14):eaaz4344. doi:10.1126/sciadv.aaz4344
   PubMed Web of Science ®Google Scholar
• Lin H, Wu T, Peng L, et al. Lnc-MAP6-1:3 knockdown inhibits osteosarcoma progression by modulating Bax/Bcl-2 and Wnt/β-catenin pathways. Int J Med Sci. 2020;17(15):2248–2256. doi:10.7150/ijms.47405
   PubMed Web of Science ®Google Scholar
• Hauge H, Patzke S, Aasheim HC. Characterization of the FAM110 gene family. Genomics. 2007;90(1):14–27. doi:10.1016/j.ygeno.2007.03.002
   PubMed Web of Science ®Google Scholar
• Xie M, Cai L, Li J, et al. FAM110B inhibits non-small cell lung cancer cell proliferation and invasion through inactivating Wnt/β-Catenin Signaling. Onco Targets Ther. 2020;13:4373–4384. doi:10.2147/OTT.S247491
   PubMed Web of Science ®Google Scholar
• Jin X, Simmons SK, Guo A, et al. In vivo Perturb-Seq reveals neuronal and glial abnormalities associated with autism risk genes. Science. 2020;370:6520. doi:10.1126/science.aaz6063
   Web of Science ®Google Scholar
• Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16(4):215–237. doi:10.2165/00003088-198916040-00002
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–338. doi:10.1038/nrc1074
   PubMed Web of Science ®Google Scholar
• Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res. 2006;12(18):5491–5495. doi:10.1158/1078-0432.CCR-06-0747
   PubMed Web of Science ®Google Scholar
• Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994;12(11):2248–2253. doi:10.1200/JCO.1994.12.11.2248
   PubMed Web of Science ®Google Scholar
• Ogura K, Ohnuma T, Minamide Y, et al. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations. Clin Cancer Res. 2005;11(14):5104–5111. doi:10.1158/1078-0432.CCR-05-0217
   PubMed Web of Science ®Google Scholar
• Zhu WP, Liu ZY, Zhao YM, et al. Dihydropyrimidine dehydrogenase predicts survival and response to interferon-α in hepatocellular carcinoma. Cell Death Dis. 2018;9(2):69. doi:10.1038/s41419-017-0098-0
   PubMedGoogle Scholar
• Kato H, Naiki-Ito A, Suzuki S, Et A. DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer. Carcinogenesis. 2021;42(7):940–950. doi:10.1093/carcin/bgab017
   PubMed Web of Science ®Google Scholar